Tom 19 (2024): Continuous Publishing
Artykuł przeglądowy
Opublikowany online: 2024-05-02
Wyświetlenia strony
232
Wyświetlenia/pobrania artykułu
96
Związek procesu zapalnego ze współwystępowaniem depresji i chorób sercowo-naczyniowych oraz możliwości terapeutyczne.
1
, 1, 2
, 1, 2
DOI: 10.5603/fc.99197
Folia Cardiologica 2024;19:99-105.
Streszczenie
Choroby sercowo-naczyniowe (CVD, cardiovascular diseases) oraz depresja zajmują czołowe miejsca wśród najczęściej występujących chorób w populacji ogólnej. W ostatnim czasie przeprowadzono wiele badań nad zapalną komponentą tych chorób. Nie jest jasny związek przyczynowo-skutkowy odpowiedzialny za tak częste ich współistnienie. Wśród mechanizmówzwiązanych z rozwojem depresji wyodrębnione zostały między innymi zachwianie osi jelita-mózg, zaburzenia aktywności mikrogleju, zwiększone stężenie CRP (C reactive protein), IL-6 (Interleukine 6) i stres oksydacyjny. CVD wiążą się z aktywacją inflamosomu NRLP-3 (NOD-like receptor protein 3), wzrostem stężenia hsCRP (highly sensitive C reactive protein) oraz interleukin: IL-1β, IL-6, IL-18, dysfunkcją osi jelita-mózg i stresem oksydacyjnym. Celem pracy jest ustalenie związku pomiędzy CVD, a depresją w kontekście stanu zapalnego w organizmie (systemic inflammation) oraz przegląd związków wpływających na redukcję lub modulację stanu zapalnego, które potencjalnie mogłyby zostać wykorzystane klinicznie w redukcji ryzyka sercowo-naczyniowego wśród pacjentów z depresją.
Słowa kluczowe: depresjachoroby sercowo-naczyniowezapalenie
Referencje
- Krittanawong C, Maitra NS, Qadeer YK, et al. Association of Depression and Cardiovascular Disease. Am J Med. 2023; 136(9): 881–895.
- Bahall M. Prevalence and associations of depression among patients with cardiac diseases in a public health institute in Trinidad and Tobago. BMC Psychiatry. 2019; 19(1): 4.
- Zhang M, Chen J, Yin Z, et al. The association between depression and metabolic syndrome and its components: a bidirectional two-sample Mendelian randomization study. Transl Psychiatry. 2021; 11(1): 633.
- Li GHY, Cheung CL, Chung AKK, et al. Evaluation of bi-directional causal association between depression and cardiovascular diseases: a Mendelian randomization study. Psychol Med. 2022; 52(9): 1765–1776.
- Carabotti M, Scirocco A, Maselli MA, et al. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015; 28(2): 203–209.
- Yin R, Zhang K, Li Y, et al. Lipopolysaccharide-induced depression-like model in mice: meta-analysis and systematic evaluation. Front Immunol. 2023; 14.
- Singhal G, Baune BT. Microglia: an interface between the loss of neuroplasticity and depression. Front Cell Neurosci. 2017; 11: 270.
- Osimo EF, Baxter LJ, Lewis G, et al. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019; 49(12): 1958–1970.
- Kakeda S, Watanabe K, Katsuki A, et al. Relationship between interleukin (IL)-6 and brain morphology in drug-naïve, first-episode major depressive disorder using surface-based morphometry. Sci Rep. 2018; 8(1): 10054.
- Kelly KM, Smith JA, Mezuk B. Depression and interleukin-6 signaling: a mendelian randomization study. Brain Behav Immun. 2021; 95: 106–114.
- Köhler CA, Freitas TH, Maes M, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017; 135(5): 373–387.
- Neupane SP, Daray FM, Ballard ED, et al. Immune-related biomarkers and suicidal behaviors: A meta-analysis. Eur Neuropsychopharmacol. 2023; 75: 15–30.
- Bhatt S, Nagappa AN, Patil CR. Role of oxidative stress in depression. Drug Discov Today. 2020; 25(7): 1270–1276.
- Goswami SK, Ranjan P, Dutta RK, et al. Management of inflammation in cardiovascular diseases. Pharmacol Res. 2021; 173: 105912.
- Kuppa A, Tripathi H, Al-Darraji A, et al. C-Reactive protein levels and risk of cardiovascular diseases: a two-sample bidirectional mendelian randomization study. Int J Mol Sci. 2023; 24(11).
- Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021; 73(3): 924–967.
- Li D, Lu Y, Yuan S, et al. Gut microbiota-derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis. Am J Clin Nutr. 2022; 116(1): 230–243.
- Qian B, Zhang K, Li Y, et al. Update on gut microbiota in cardiovascular diseases. Front Cell Infect Microbiol. 2022; 12.
- Guo Yi, Luo S, Ye Y, et al. Intermittent fasting improves cardiometabolic risk factors and alters gut microbiota in metabolic syndrome patients. J Clin Endocrinol Metab. 2021; 106(1): 64–79.
- Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377(12): 1119–1131.
- Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019; 381(26): 2497–2505.
- Nidorf SM, Fiolet ATL, Mosterd A, et al. LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020; 383(19): 1838–1847.
- Henein MY, Vancheri S, Longo G, et al. The role of inflammation in cardiovascular disease. Int J Mol Sci. 2022; 23(21).
- Stewart JC, Patel JS, Polanka BM, et al. Effect of modernized collaborative care for depression on depressive symptoms and cardiovascular disease risk biomarkers: eIMPACT randomized controlled trial. Brain Behav Immun. 2023; 112: 18–28.
- Ding J, Zhang Yi. Associations of dietary vitamin C and E intake with depression. A meta-analysis of observational studies. Front Nutr. 2022; 9.
- Violi F, Nocella C, Loffredo L, et al. Interventional study with vitamin E in cardiovascular disease and meta-analysis. Free Radic Biol Med. 2022; 178: 26–41.
- Jia S, Hou Y, Wang D, et al. Flavonoids for depression and anxiety: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2023; 63(27): 8839–8849.
- Parmenter BH, Croft KD, Hodgson JM, et al. An overview and update on the epidemiology of flavonoid intake and cardiovascular disease risk. Food Funct. 2020; 11(8): 6777–6806.
- Abuelezz SA, Hendawy N, Magdy Y. Targeting oxidative stress, cytokines and serotonin interactions via indoleamine 2, 3 dioxygenase by coenzyme Q10: role in suppressing depressive like behavior in rats. J Neuroimmune Pharmacol. 2017; 12(2): 277–291.
- Alehagen U, Johansson P, Svensson E, et al. Improved cardiovascular health by supplementation with selenium and coenzyme Q10: applying structural equation modelling (SEM) to clinical outcomes and biomarkers to explore underlying mechanisms in a prospective randomized double-blind placebo-controlled intervention project in Sweden. Eur J Nutr. 2022; 61(6): 3135–3148.
- Liao Y, Xie Bo, Zhang H, et al. Efficacy of omega-3 pufas in depression: a meta-analysis. Transl Psychiatry. 2019; 9(1): 190.
- Bersch-Ferreira ÂC, Sampaio GR, Gehringer MO, et al. Association between polyunsaturated fatty acids and inflammatory markers in patients in secondary prevention of cardiovascular disease. Nutrition. 2017; 37: 30–36.
- Fusar-Poli L, Vozza L, Gabbiadini A, et al. Curcumin for depression: a meta-analysis. Crit Rev Food Sci Nutr. 2020; 60(15): 2643–2653.
- Zeng L, Yang T, Yang K, et al. Efficacy and safety of curcumin and extract in the treatment of arthritis: a systematic review and meta-analysis of randomized controlled trial. Front Immunol. 2022; 13.
- Ansari F, Pourjafar H, Tabrizi A, et al. The effects of probiotics and prebiotics on mental disorders: a review on depression, anxiety, alzheimer, and autism spectrum disorders. Curr Pharm Biotechnol. 2020; 21(7): 555–565.
- Dixon A, Robertson K, Yung A, et al. Efficacy of probiotics in patients of cardiovascular disease risk: a systematic review and meta-analysis. Curr Hypertens Rep. 2020; 22(9): 74.
- Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013; 70(1): 31–41.
- Gill H, Rodrigues NB, Mansur RB, et al. The effect of adjunctive infliximab treatment on future cardiovascular disease risk in patients with bipolar disorder. J Affect Disord. 2022; 316: 273–279.
- Kappelmann N, Lewis G, Dantzer R, et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018; 23(2): 335–343.
- Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012; 379(9822): 1214–1224.
